Essential Clinical Anatomy of the Nervous System || Acknowledgments
- 作者,
- 文件大小173.83KB
- 发表时间2015
- DOI10.1016/B978-0-12-802030-2.00014-5
The cost–effectiveness of clopidogrel: a review by indicationSchleinitz, Mark D · Expert Review of Pharmacoeconomics & Outcomes Research · 2006
Cost–Effectiveness of Clopidogrel-Aspirin Versus Aspirin Alone for Acute Tia and Minor StrokePan, Y.; Wang, Y.L.; Liu, G.; Zhao, K.; Wang, Y. · Value in Health · 2014
Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart DiseaseGaspoz, Jean-Michel; Coxson, Pamela G.; Goldman, Paula A.; Williams, Lawrence W.; Kuntz, Karen M.; Hunink, M.G. Myriam; Goldman, Lee · New England Journal of Medicine · 2002
PCV69 COST EFFECTIVENESS ANALYSIS OF TICAGRELOR VERSUS CLOPIDOGREL IN STEMI PATIENTS FROM NATIONAL HEART INSTITUTE PERSPECTIVE IN EGYPTAbourawash, A. · Value in Health · 2019
PCV44 COST EFFECTIVENESS OF CLOPIDOGREL TREATMENT VERSUS ASPIRIN TREATMENT IN SOUTH KOREAN PATIENTS WITH ATHEROTHROBOSIS: RESULTS OF THE CAPRIE (CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS AT RISK OF ISCHEMIC EVENTS) STUDYBM Yang; S Shin; JH Lee · 2009
Cost–effectiveness of using <i>CYP2C19</i> genotype to guide selection of clopidogrel or ticagrelor in AustraliaSorich, Michael J; Horowitz, John D; Sorich, Wassana; Wiese, Michael D; Pekarsky, Brita; Karnon, Jonathan D · Pharmacogenomics · 2013
Cost–Effectiveness of Clopidogrel Plus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation in Whom Warfarin Is UnsuitableCraig I. Coleman; Andrew D. Straznitskas; Diana M. Sobieraj; Jeffrey Kluger; Moise W. Anglade · 2012
Cost Effectiveness Analysis Of Ticagrelor Versus Generic Clopidogrel In The Treatment Of Patients With Acute Coronary Syndrome In SpainCapel, M.; Lopez-Sendon, J.L.; Heras, M.; Carrera, F.J.; Brosa, M. · Value in Health · 2014
ReplyMurphy, Sabina A.; Cannon, Christopher P.; Blazing, Michael A.; Giugliano, Robert P.; Tershakovec, Andrew M.; Braunwald, Eugene · Journal of the American College of Cardiology · 2016
ReplyMurphy, Sabina A.; Cannon, Christopher P.; Blazing, Michael A.; Giugliano, Robert P.; Tershakovec, Andrew M.; Braunwald, Eugene · Journal of the American College of Cardiology · 2016
ReplyBohula, Erin A.; Morrow, David A.; Giugliano, Robert P.; Cannon, Christopher P.; Braunwald, Eugene · Journal of the American College of Cardiology · 2017
Short Stay Management of Chest Pain ||Cannon, Christopher P.; Peacock, William Franklin · 2009
Authors' ReplyReed, Grant W.; Guo, Jianping; Cannon, Christopher P.; Kumar, Amit; Aranki, Sary; Shekar, Prem; Agnihotri, Arvind; Maree, Andrew O.; McLean, Dalton S.; Rosenfield, Kenneth · Clinical Cardiology · 2015
STREAM characterisation correction – Authors' replyReed, Grant W; Cannon, Christopher P · The Lancet · 2017
Don’t stop the statin!Cannon, Christopher P · European Heart Journal · 2019
Cost studies in clinical trialsShaya, Fadia T; Samant, Navendu · Expert Review of Pharmacoeconomics & Outcomes Research · 2004
Pharmacoeconomics of etravirineFullerton, DS; Watson, Mary Jane; Anderson, David; Witek, James; Martin, Silas C; Mrus, Joseph M · Expert Review of Pharmacoeconomics & Outcomes Research · 2010
Multi-Attribute Preference FunctionsTorrance, George W.; Furlong, William; Feeny, David; Boyle, Michael · PharmacoEconomics · 1995
Dabigatran EtexilateMcKeage, Kate · PharmacoEconomics · 2012
Sickle Cell AnaemiaNietert, Paul J.; Silverstein, Marc D.; Abboud, Miguel R. · PharmacoEconomics · 2002
Analysis Sans FrontièresSculpher, Mark J; Drummond, Michael F · PharmacoEconomics · 2006
Pharmaceutical Risk-Sharing AgreementsCook, Joseph P; Vernon, John A; Manning, Richard · PharmacoEconomics · 2008
Pharmacoeconomics in the New MillenniumThwaites, Rob; Townsend, Raymond J. · PharmacoEconomics · 1998